Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 352

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Randomized double‐blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (infliximab) versus placebo in active spondylarthropathy

Van den Bosch, Filip, Kruithof, Elli, Baeten, Dominique, Herssens, Annemie, de Keyser, Filip, Mielants, Herman, Veys, Eric M.·2002·Arthritis & Rheumatism

Abstract

Objective: To confirm in a placebo‐controlled trial the safety and efficacy profile of infliximab in short‐term treatment of patients with active spondylarthropathy (SpA). Methods: Forty patients with active SpA were randomly assigned to receive an intravenous loading dose (weeks 0, 2, and 6) of 5 mg/kg infliximab or placebo. Evaluations for efficacy and safety were performed at weeks 1, 2, 6, 8, and 12. The primary end points of this study were the improvements in patient and physician global assessments of disease activity on a 100‐mm visual analog scale. Results: Both primary end points improved significantly in the infliximab group compared with the baseline value, with no improvement in the placebo group. As early as week 2 and sustained up to week 12, there was a highly statistically significant difference between the values for these 2 end points in the infliximab versus the placebo group. In most of the other assessments of disease activity (laboratory measures, assessments of specific peripheral and/or axial disease), significant improvements were observed in the infliximab group compared with the baseline value and compared with placebo. Minor adverse events not causing discontinuation were equally observed in both treatment groups. There was one severe drug‐related adverse event, in which a patient developed disseminated tuberculosis. Conclusion: Tumor necrosis factor α blockade with infliximab in patients with active SpA was well tolerated and resulted in significant clinical and laboratory improvements in this short‐term, placebo‐controlled study. However, the occurrence of tuberculosis in one patient necessitates strict inclusion criteria and long‐term followup.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/art.511

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 30 references

Cited by

See all 352

Metadata

Authors
Van den Bosch, F., Kruithof, E., Baeten, D., Herssens, A., de Keyser, F., Mielants, H., & Veys, E. M.
Venue
Arthritis & Rheumatism
Publisher
Wiley
Published
2002-03
Volume
46
Issue
3
Pages
755-765
ISSN
  • 0004-3591 (ISSN-L)
  • 1529-0131
OpenAlex
W2006154561
Cited by
352
References
30
FWCI
28.34
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Randomized double‐blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (infliximab) versus placebo in active spondylarthropathy. https://app.cochat.ai/papers/10.1002/art.511
The paper
Van den Bosch, F., Kruithof, E., Baeten, D., Herssens, A., de Keyser, F., Mielants, H., & Veys, E. M. (2002). Randomized double‐blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (infliximab) versus placebo in active spondylarthropathy. Arthritis & Rheumatism. https://doi.org/10.1002/art.511

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.